NCT04943211View on ClinicalTrials.gov

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Histiocytosis
Interventions
DRUG

fluorodeoxyglucose (18F-FDG)

max 6 MGBq/kg, no more than 100

Trial Locations (1)

01-211

RECRUITING

Mother and Child Institute, Warsaw

All Listed Sponsors
collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

collaborator

Łukasiewicz Research Network

UNKNOWN

collaborator

Wrocław University of Environmental and Life Sciences

UNKNOWN

lead

Anna Raciborska

OTHER